XOMA Co. (NASDAQ:XOMA - Get Free Report) Director Joseph M. Limber acquired 5,243 shares of the firm's stock in a transaction that occurred on Monday, April 7th. The stock was bought at an average price of $25.60 per share, for a total transaction of $134,220.80. Following the completion of the transaction, the director now owns 10,000 shares of the company's stock, valued at $256,000. The trade was a 110.22 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.
XOMA Stock Down 2.4 %
Shares of XOMA opened at $18.76 on Wednesday. XOMA Co. has a 1 year low of $18.35 and a 1 year high of $35.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. The stock has a 50 day simple moving average of $22.61 and a two-hundred day simple moving average of $26.39. The firm has a market cap of $224.73 million, a P/E ratio of -5.39 and a beta of 1.00.
XOMA (NASDAQ:XOMA - Get Free Report) last released its earnings results on Monday, March 17th. The biotechnology company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.17). The business had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.75 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. On average, analysts forecast that XOMA Co. will post -1.41 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of XOMA. Nuveen Asset Management LLC lifted its stake in shares of XOMA by 3.8% in the 4th quarter. Nuveen Asset Management LLC now owns 14,363 shares of the biotechnology company's stock valued at $377,000 after acquiring an additional 527 shares during the last quarter. BNP Paribas Financial Markets increased its stake in XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company's stock worth $43,000 after purchasing an additional 795 shares during the period. New York State Common Retirement Fund boosted its stake in shares of XOMA by 51.2% during the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company's stock valued at $62,000 after purchasing an additional 800 shares during the period. Eversept Partners LP boosted its stake in shares of XOMA by 1.2% during the fourth quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company's stock valued at $2,508,000 after purchasing an additional 1,128 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of XOMA by 0.6% in the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company's stock worth $4,840,000 after purchasing an additional 1,138 shares during the last quarter. 95.92% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of research firms have commented on XOMA. StockNews.com cut shares of XOMA from a "hold" rating to a "sell" rating in a research note on Thursday, April 3rd. HC Wainwright reissued a "buy" rating and issued a $104.00 target price on shares of XOMA in a research note on Friday, March 28th.
Read Our Latest Research Report on XOMA
About XOMA
(
Get Free Report)
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
